Skip to main content
. 2020 Nov 20:10.2217/fmb-2020-0118. doi: 10.2217/fmb-2020-0118

Table 1. Main published works in 2020 regarding drug candidates tested against SARS-CoV, MERS-CoV and SARS-CoV-2, in terms of drug, target binding, type of assays and its traditional uses.

Drug Target Assays Usual treatment Ref.
Arbidol Binds to hemagglutinin In vitro Influenza, arboviruses [47]
Atazanavir Inhibition of the 3CLPRO In silico, in vitro HIV [48]
Chloroquine Immunomodulatory effects, increase endosomal pH required for virus In vitro, clinical trial Malaria [49,50]
Dactinomycin RNA synthesis inhibitor In silico Cancer [51]
Darunavir Protease inhibitor In silico HIV [48,52]
Dolutegravir Protease inhibitor In silico HIV [42]
Efavirenz Inhibition of the 3CLPRO In silico HIV [42]
Emetine Inhibits the replication of RNA viruses In vitro Amoebiasis [53]
Emodin Blocked the interaction between the spike and ACE2 In silico, in vitro Cancer [51]
Favipiravir RNA-dependent RNA polymerase (RdRp) inhibitor In vitro, clinical trial Influenza [49,54]
Galidesivir Bind RdRp In silico Hepatitis C virus (HCV) [55]
Hydroxychloroquine Immunomodulatory effects, increase endosomal pH required for virus In vitro, clinical trial Malaria [50,56]
Ivermectin   In vitro Parasites [57]
Lopinavir-ritonavir inhibition of the 3CLPRO In vitro, clinical trial HIV [58]
Melatonin regulates ACE2 expression In silico Several including insomnia [45]
Mercaptopurine Inhibition Papain-like protease In silico, in vitro Cancer and auto-immune diseases [45]
Remdesivir Inhibition the RdRp/Seems to inhibit of the 3CLPRO In silico, in vitro, in vivo HIV/Ebola [42,43,46,49]
Ribavirin Inhibits RdRp In silico HCV, respiratory syncytial virus (RSV) [59]
Saquinavir inhibition of the 3CLPRO In silico HIV [52]
Sirolimus Inhibitor of mTOR In silico Antifungal and cancer [45]
Sofosbuvir Bind RdRp In silico HCV [55,59]
Tenofovir Bind RdRp In silico HIV [49]
Tirolone Inducer of interferon In vitro Influenza, hepatitis, viral encephalitis and others [60,61]
Toremifene Destabilizing the virus membrane glycoprotein In silico, in vitro Cancer [45]

Sirolimus and dactinomycin.

Melatonin and mercaptopurine.